Satraplatin

Satraplatin Struktur
129580-63-8
CAS-Nr.
129580-63-8
Englisch Name:
Satraplatin
Synonyma:
JM 216;C081294;BMY 45594;BMS 182751;SATRAPLATIN;Satraplatin(JM216);BMS-182751;BMY-45594;JM-216;bis(acetato-o)amminedichloro(cyclohexanamine)-pt;Bis-acetatoamminedichlorocyclohexylamine platinum(iv);(OC-6-43)-bis(acetato)amminedichloro(cyclohexylamine)platinum
CBNumber:
CB2675796
Summenformel:
C10H20Cl2N2O4Pt
Molgewicht:
498.26
MOL-Datei:
129580-63-8.mol

Satraplatin Eigenschaften

storage temp. 
Store at -20°C
Löslichkeit
DMF: 0.16 mg/mL; DMSO: 0.5 mg/mL
Aggregatzustand
Powder

Sicherheit

Toxizität LD50 in mice (mg/kg): 30 i.p.; 330 orally (Kelland)

Satraplatin Chemische Eigenschaften,Einsatz,Produktion Methoden

Verwenden

Antineoplastic.

Definition

ChEBI: A platinum coordination entity that consists of a central platunum atom bound to chloro (x2), acetate (x2), amino, and cyclohexylamino groups. Used for treatment of advanced prostate cancer.

Pharmazeutische Anwendungen

Satraplatin (JM216, cis,trans,cis-[PtCl2(OAc)2(NH3)(C6H5NH2)]) is a Pt(IV) or Pt4+ complex, which is active by oral administration, as it is more hydrophobic than cisplatin. This form of administration is very attractive because of the convenience and freedom it provides to the patient. Satraplatin also has a milder toxicity profile and is shows no cross-resistance with cisplatin. Satraplatin in combination with prednisone has completed phase III clinical trials against hormone-refractory prostate cancer. The results were very encouraging, but the overall survival rate did not improve significantly enough. As a result, the fast-track approval of the FDA was not granted.
Structurally, satraplatin consists of a Pt(IV) centre, which is coordinated by six ligands forming a close to octahedral geometry. In general, octahedral Pt(IV) complexes (low-spin d6) are much more kinetically inert than square planar Pt(II) complexes.

Clinical Use

This newest organometallic agent currently is in clinical trials as a second-line agent for the treatment of hormone-refractory prostate cancer . There is hope that it also will find value in ovarian cancer and small cell lung cancer.

Nebenwirkungen

As with other organoplatinum complexes, the diaquo form is active. At this early stage, the toxicity profile appears to be mild, with dose-related myelosuppression, particularly neutropenia and thrombocytopenia, being the major use-limiting side effect.

Stoffwechsel

Unlike the square-planar Pt(II) complexes currently on the market, it is active by the oral route. It is metabolized quickly in whole blood, producing up to six metabolites. The major metabolite is the desacetoxy analogue.

Satraplatin Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


Satraplatin Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global( 109)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
career henan chemical co
+86-0371-86658258
sales@coreychem.com China 29914 58
BOC Sciences
+1-631-485-4226
inquiry@bocsci.com United States 19553 58
Chongqing Chemdad Co., Ltd
+86-023-61398051 +8613650506873
sales@chemdad.com China 39916 58
CONIER CHEM AND PHARMA LIMITED
+8618523575427
sales@conier.com China 49390 58
SIMAGCHEM CORP
+86-13806087780
sale@simagchem.com China 17367 58
HANGZHOU CLAP TECHNOLOGY CO.,LTD
86-571-88216897,88216896 13588875226
sales@hzclap.com CHINA 6313 58
AFINE CHEMICALS LIMITED
0571-85134551
info@afinechem.com CHINA 15377 58
Finetech Industry Limited
+86-27-87465837 +8618971612321
info@finetechnology-ind.com China 9702 58
Wuhan Fortuna Chemical Co., Ltd
+86-27-59207850 +86-13986145403
info@fortunachem.com China 5988 58
Dayang Chem (Hangzhou) Co.,Ltd.
571-88938639 +8617705817739
info@dycnchem.com CHINA 52867 58

129580-63-8()Verwandte Suche:


  • bis(acetato-o)amminedichloro(cyclohexanamine)-pt
  • platinum (lv) cis-dichloro-trans-bis(acetato-o)ammine(cyclohexanamine)
  • SATRAPLATIN
  • JM 216
  • Bis-acetatoamminedichlorocyclohexylamine platinum(iv)
  • C081294
  • Platinum, bis(acetato-o)amminedichloro(cyclohexanamine)-, (oc-6-43)-
  • Satraplatin(JM216)
  • (OC-6-43)-bis(acetato)amminedichloro(cyclohexylamine)platinum
  • BMS 182751
  • BMY 45594
  • Cis-dichloro-trans-diacetoxyl-cis-amino, cyclohexaneplatinum (IV)
  • BMS-182751;BMY-45594;JM-216
  • 129580-63-8
  • C10H22Cl2N2O4Pt
  • C6H13NC4H6Cl2O4PtH3N
  • Anticancer
Copyright 2019 © ChemicalBook. All rights reserved